Abstract: A method of performing background light subtraction in an infra-red (IR) illuminated image depicting a scene, comprises: providing a rolling shutter image sensor; providing an IR light source configured to be turned on and off; changing an on-off status of the IR light source a plurality of times while capturing an image; capturing two or more image frames each image frame comprising: a first set of lines of pixels comprising image data captured with the IR light turned on; a second set of lines of pixels comprising image data captured with the IR light turned off; creating an IR-illuminated image; creating a non-IR-illuminated image; subtracting background light from the IR-illuminated image using pixel values in the non-IR-illuminated image.

Abstract: A method of performing background light subtraction in an infra-red (IR) illuminated image depicting a scene, comprises: providing a rolling shutter image sensor; providing an IR light source configured to be turned on and off; changing an on-off status of the IR light source a plurality of times while capturing an image; capturing two or more image frames each image frame comprising: a first set of lines of pixels comprising image data captured with the IR light turned on; a second set of lines of pixels comprising image data captured with the IR light turned off; creating an IR-illuminated image; creating a non-IR-illuminated image; subtracting background light from the IR-illuminated image using pixel values in the non-IR-illuminated image.

Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being a PD-1/PD-L1 inhibitor, and component B being a targeted thorium conjugate. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of breast and prostate cancer.

Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.

Abstract: The invention relates to a corrosion and wear resistance cold work tool steel. The steel includes the following main components (in wt. %): C 0.3-0.8, N 1.0-2.2, (C+N) 1.3-2.2, C/N 0.17-0.50, Si?1.0, Mn 0.2-2.0, Cr 13-30, Mo 0.5-3.0, V 2.0-5.0, balance optional elementals, iron and impurities.